New Oral Anticoagulants and the Cancer Patient

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2013 Dec 10

PMID 24319019

Citations 66

Authors

Nicholas J Short

Jean M Connors

Affiliations

Soon will be listed here.

Abstract

Indications for anticoagulation are common in patients with malignancy. Cancer patients have an increased risk of developing venous thromboembolic events or may have other indications for anticoagulation, such as atrial fibrillation. New oral anticoagulants (NOACs) are now available that offer increased options for anticoagulation beyond the traditional vitamin K antagonists and low molecular weight heparins that have long been the cornerstone of treatment. This review will focus on the three NOACs that are currently approved for use in the U.S.: the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors, apixaban and rivaroxaban. Oncologists are likely to encounter an increasing number of patients taking these agents at the time of their cancer diagnosis or to have patients who develop indications for anticoagulation during the course of their disease. The basic pharmacology, current clinical indications, and approach to the use of NOACs in the cancer patient will be reviewed.

Citing Articles

Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count.

Isingizwe Z, Meelheim B, Benbrook D Cancers (Basel). 2024; 16(21).

PMID: 39518024 PMC: 11545395. DOI: 10.3390/cancers16213583.

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.

Napolitano M, Siragusa S Cancers (Basel). 2023; 15(18).

PMID: 37760609 PMC: 10526875. DOI: 10.3390/cancers15184640.

Construction and validation of a nomogram of risk factors for new-onset atrial fibrillation in advanced lung cancer patients after non-surgical therapy.

Chen J, Cao S, Jin Y, Rong W, Wang H, Xi S Front Oncol. 2023; 13:1125592.

PMID: 37519821 PMC: 10374250. DOI: 10.3389/fonc.2023.1125592.

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review.

Gornicki T, Buldys K, Zielinska D, Chabowski M Cancers (Basel). 2023; 15(10).

PMID: 37345034 PMC: 10216040. DOI: 10.3390/cancers15102697.

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study).

Oride T, Sawada K, Shimizu A, Kinose Y, Takiuchi T, Kodama M Thromb J. 2023; 21(1):57.

PMID: 37183245 PMC: 10184411. DOI: 10.1186/s12959-023-00500-8.

References

Vakkalagadda B, Frost C, Byon W, Boyd R, Wang J, Zhang D . Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016; 16(2):119-27. DOI: 10.1007/s40256-015-0157-9. View

Walenga J, Adiguzel C . Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010; 64(7):956-67. DOI: 10.1111/j.1742-1241.2009.02286.x. View

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs R, Brenner B . International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2012; 11(1):56-70. DOI: 10.1111/jth.12070. View

Szucs T, Bramkamp M . Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost. 2006; 4(6):1180-5. DOI: 10.1111/j.1538-7836.2006.01890.x. View

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

Merkow R, Bilimoria K, McCarter M, Cohen M, Barnett C, Raval M . Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011; 254(1):131-7. DOI: 10.1097/SLA.0b013e31821b98da. View

Kearon C, Akl E, Comerota A, Prandoni P, Bounameaux H, Goldhaber S . Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-e496S. PMC: 3278049. DOI: 10.1378/chest.11-2301. View

Lyman G, Khorana A, Kuderer N, Lee A, Arcelus J, Balaban E . Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31(17):2189-204. DOI: 10.1200/JCO.2013.49.1118. View

Buller H, Prins M, Lensin A, Decousus H, Jacobson B, Minar E . Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14):1287-97. DOI: 10.1056/NEJMoa1113572. View

10.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

11.

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

12.

Godier A, Miclot A, Le Bonniec B, Durand M, Fischer A, Emmerich J . Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2011; 116(1):94-102. DOI: 10.1097/ALN.0b013e318238c036. View

13.

Rose A, Sharman J, Ozonoff A, Henault L, Hylek E . Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007; 22(7):997-1002. PMC: 2219727. DOI: 10.1007/s11606-007-0228-y. View

14.

Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J . A specific antidote for dabigatran: functional and structural characterization. Blood. 2013; 121(18):3554-62. DOI: 10.1182/blood-2012-11-468207. View

15.

Jonas D, Shilliday B, Laundon W, Pignone M . Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making. 2009; 30(2):206-16. PMC: 4181607. DOI: 10.1177/0272989X09343960. View

16.

Akl E, Labedi N, Barba M, Terrenato I, Sperati F, Muti P . Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011; (6):CD006650. DOI: 10.1002/14651858.CD006650.pub3. View

17.

Mandala M, Falanga A, Roila F . Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 Suppl 6:vi85-92. DOI: 10.1093/annonc/mdr392. View

18.

Lu G, DeGuzman F, Hollenbach S, Karbarz M, Abe K, Lee G . A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19(4):446-51. DOI: 10.1038/nm.3102. View

19.

Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

20.

Marchetti S, Mazzanti R, Beijnen J, Schellens J . Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007; 12(8):927-41. DOI: 10.1634/theoncologist.12-8-927. View